6:00 p.m. CEST – Adocia (Euronext Paris: FR0011184241 – ADOC), a clinical-stage biopharmaceutical company specializing in the research and development of innovative therapeutic solutions for the treatment of diabetes and other metabolic diseases, today announces its participation in the following investor events :
• Investor Access (October 6 and 7, 2022), in Paris
• Biotech Agora (November 3, 2022), in Paris
• Kepler Cheuvreux – Life Sciences Day (November 21, 2022), digital
As part of these professional meetings with the financial community, through “one-to-one” or “one-to-few” formats, Adocia’s management will discuss the latest clinical and scientific advances in its most (BioChaperone Lispro, BioChaperone Combo, M1Pram) and will detail the next expected catalysts relating in particular to the use of breakthrough technologies AdoShell and AdOral.